ARTICLE | Company News
Exelixis, Merck deal
January 2, 2012 8:00 AM UTC
Exelixis granted Merck exclusive, worldwide rights to its preclinical phosphoinositide 3-kinase (PI3K) delta program, including lead inhibitor XL499 and related compounds. Exelixis will receive $12 ...